Skip to content
MarketScale
‹ Back to Industries

Sciences

The Fungus from The Last of Us Could Help Fight Cancer

The Last of Us, HBO’s videogame-inspired zombie TV epic, opened to rave reviews last month. This drama, led by Game of Thrones stars Pedro Pascal and Bella Ramsey, shows a post-apocalyptic world that has been ravaged by the corydceps fungus after the fungus adapts for survival in the human body. Scarily enough, the fungus from…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Leslie Samuel · Cancer ResearchCordyceps FungusFungiMycology
Share

Key takeaways

01

The Last of Us, HBO’s videogame-inspired zombie TV epic, opened to rave reviews last month.

02

This drama, led by Game of Thrones stars Pedro Pascal and Bella Ramsey, shows a post-apocalyptic world that has been ravaged by the corydceps fungus after the fungus adapts for survival in the human body.

03

Scarily enough, the fungus from…

The Last of Us, HBO’s videogame-inspired zombie TV epic, opened to rave reviews last month. This drama, led by Game of Thrones stars Pedro Pascal and Bella Ramsey, shows a post-apocalyptic world that has been ravaged by the corydceps fungus after the fungus adapts for survival in the human body. Scarily enough, the fungus from The Last of Us is very, very real, and it’s turned many more casual eyes to the world of mycology. Should people give the cordyceps fungus the horror treatment, though?

Cordyceps’ claim to fame isn’t off base; some species of the fungus are known to infect insects and basically, turn them into zombies. Interest in the series has raised questions of whether a cordyceps-fueled pandemic can actually threaten humanity. Experts in the field of mycology say it is highly improbable and would require major genetic changes, which would probably develop over the course of millions of years.

Although the fungus may be terrifying for invertebrates, outside of The Last of Us’s lore, cordyceps is actually quite useful for humans. It is a widely used ingredient in traditional Chinese medicine, and recent research shows it may even have anti-cancerous properties. So as media consumers clamor for cordyceps content, how is the science community approaching research around the zombie fungus? Leslie Samuel, founder of Interactive Biology, a Master’s in Neurobiology holder, and an experienced science educator, breaks down some of the most recent research surrounding the fungus from The Last of Us.

Leslie’s Thoughts:

“In the field of mycology, which is the study of fungi, there’s been a lot of interest in the cordyceps fungus. That’s the same type of fungus that the show, The Last of Us, is based on. We know that certain species of that fungus can infect ants, turning them into zombies, and when they get infected, those ants will climb up a tree and bite into it, basically committing suicide as the fungus takes over their bodies and [causes] them to release more spores so that they can infect more ants. And the cycle continues like in The Last of Us, but with ants.

But there are also studies that show that certain species of the cordyceps fungus have potential anti-cancer effects. They’ve demonstrated that certain extracts from some species of the cordyceps fungus seems to inhibit the growth of liver cancer. And other studies suggest that there are specific substances in some species that inhibit the inflammatory response in certain immune system cells in mice. Now, there’s still a lot more research that needs to be done to confirm that these effects can actually help in therapies in the future. But this entire field of mycology is fascinating, with these fungi having both harmful and potentially life-saving properties.”

About the author

Leslie Samuel

Leslie Samuel's journey is a testament to determination and passion. Although his dream of becoming a university professor was initially hampered by the lack of a Ph.D., he didn't let that stop him. Instead, he embraced the digital age, becoming a prominent blogger and YouTuber. Through these platforms, Leslie shared his knowledge, effectively teaching what he would have taught in a classroom, reaching hundreds of thousands of eager learners worldwide. His online success opened doors, leading to his dream job as a university professor in a Doctor of Physical Therapy program, despite the absence of a Ph.D. However, Leslie's impact online was undeniable, prompting him to make the bold decision to transition into a full-time blogger and business coach. Today, through Interactive Biology, Leslie Samuel continues to demonstrate that Biology is not only educational but also immensely enjoyable. His journey is a shining example of how determination and innovation can turn dreams into reality.

New to MarketScale?

MarketScale is the platform Sciences companies use to turn their own experts into content like this. Want the short overview?

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Tekniplex Showcases Sustainable Materials Innovation at Paris Packaging Week 2026

Tekniplex Showcases Sustainable Materials Innovation at Paris Packaging Week 2026

At Paris Packaging Week 2026, Tekniplex showcased its latest sustainable materials innovations, emphasizing the intersection of materials science and brand storytelling. The company's booth featured a living wall and digital displays to engage a sustainability-conscious audience, highlighting advanced materials for sustainability and product performance in cosmetics packaging.

  • 01Tekniplex emphasized sustainable materials innovation at Paris Packaging Week 2026.
  • 02The company's booth featured eco-friendly design elements and immersive digital displays.
  • 03Tekniplex highlighted advancements in recyclable sealing systems and materials for cosmetics.

Apr 9, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

Leslie Samuel's journey is a testament to determination and passion. Although his dream of becoming a university professor was initially hampered by the lack of a Ph.D., he didn't let that stop him. Instead, he embraced the digital age, becoming a prominent blogger and YouTuber. Through these platforms, Leslie shared his knowledge, effectively teaching what he would have taught in a classroom, reaching hundreds of thousands of eager learners worldwide. His online success opened doors, leading to his dream job as a university professor in a Doctor of Physical Therapy program, despite the absence of a Ph.D. However, Leslie's impact online was undeniable, prompting him to make the bold decision to transition into a full-time blogger and business coach. Today, through Interactive Biology, Leslie Samuel continues to demonstrate that Biology is not only educational but also immensely enjoyable. His journey is a shining example of how determination and innovation can turn dreams into reality.